甘精胰岛素（来得时）控制血糖的疗效与赖脯胰岛素（优泌乐）相当
Insulin Glargine Controls Blood Sugar as Well as Insulin LisproNEW YORK -- March 27, 2008 -- The use of insulin glargine (a single daily injection of insulin) is as effective at controlling blood sugar for people with diabetes as insulin lispro (which has to be injected up to 3 times a day). Insulin glargine is associated with increased satisfaction among users. These are the conclusions of the authors of an article published in this week's edition of The Lancet.
Reinhard G. Bretzel, MD, PhD, Professor, Justus-Liebig-Universitat, Giessen, Germany, and colleagues conducted the APOLLO study -- A Parallel Design Comparing an Oral Antidiabetic Drug Combination Therapy With Either Lantus Once Daily or Lispro at Mealtime in Type 2 Diabetes Patients Failing Oral Treatment. This study was a 44-week trial of 418 patients recruited at 69 study sites in Europe and Australia. All patients had type 2 diabetes that was not adequately controlled by oral hypoglycaemic drugs and were randomly assigned to insulin glargine injected once daily at the same time every day (n = 205) or to insulin lispro injected 3 times per day (n = 210).
The investigators found that both groups achieved similar reductions in haemoglobin A1c, with an average decrease in the insulin glargine group of -1.7% (from 8.7% to 7.0%) and in the insulin lispro group of -1.9% (from 8.7% to 6.8%).
The authors concluded, \"A therapeutic regimen involving the addition of either basal or prandial insulin analogue is equally effective in lowering haemoglobin A1c. We conclude that insulin glargine provides a simple and effective option that is more satisfactory to patients than is lispro for early initiation of insulin therapy, since it was associated with a lower risk of hypoglycaemia, fewer injections, less blood glucose self-monitoring, and greater patient satisfaction than was insulin lispro.\"
甘精胰岛素（来得时）控制血糖的疗效与赖脯胰岛素（优泌乐）相当
使用甘精胰岛素(每日注射一次)来控制糖尿病人的血糖,其效果与赖脯胰岛素(每天注射三次)相当.甘精胰岛素在患者中的满意度与日俱增.这些结论出自本周《柳叶刀》发表的一篇文章(NEW YORK -- March 27, 2008).
德国吉森市Justus-Liebig-Universitat的Reinhard G. Bretzel教授和其同事开展APOLLO研究-- 在口服降糖药治疗失败的2型糖尿病患者中比较口服降糖药联合一天一次来得时或者餐时优泌乐的平行设计实验.该研究在欧洲和澳大利亚的69个研究地点征集了418位患者进行了为期44周的实验.所有患者均为口服降糖药不能很好控制血糖的2型糖尿病患者,他们被随机分为两组,一组每天在同一时间注射一次来得时(n = 205),另一组每天注射三次优泌乐(n = 210).研究者发现两组患者的糖化血红蛋白降低程度类似,在来得时组平均下降1.7%(从8.7% 下降到7.0%),而优泌乐组平均下降了1.9%(从8.7%下降到6.8%).作者总结道:\"一种治疗方法涉及到添加基本的胰岛素或者胰岛素类似物在降低糖化血红蛋白方面是等效的.来得时为我们提供了一种简单并有效的观点,其比早期使用优泌乐治疗更能使患者满意,因为它发生低血糖风险少,注射次数少,血糖自我监测少且为更多的患者满意.\"
页:
[1]